Armstrong, A. J., Saad, F., Oya, M., Shore, N. D., Procopio, G., Vianna, K., … Clarke, N. (2024). Association of baseline characteristics with adverse events (AEs) in the PROpel trial of olaparib (ola) plus abiraterone (abi) as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 42).

Armstrong, Andrew J., Fred Saad, Mototsugu Oya, Neal D. Shore, Giuseppe Procopio, Karina Vianna, Niven Mehra, et al. “Association of baseline characteristics with adverse events (AEs) in the PROpel trial of olaparib (ola) plus abiraterone (abi) as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 42, 2024.

Armstrong AJ, Saad F, Oya M, Shore ND, Procopio G, Vianna K, et al. Association of baseline characteristics with adverse events (AEs) in the PROpel trial of olaparib (ola) plus abiraterone (abi) as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC). In: JOURNAL OF CLINICAL ONCOLOGY. 2024.

Armstrong, Andrew J., et al. “Association of baseline characteristics with adverse events (AEs) in the PROpel trial of olaparib (ola) plus abiraterone (abi) as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC).” JOURNAL OF CLINICAL ONCOLOGY, vol. 42, no. 16, 2024.

Armstrong AJ, Saad F, Oya M, Shore ND, Procopio G, Vianna K, Mehra N, Ozguroglu M, Gedye C, Brown E, Schlurmann F, Lee JY, Joung JY, Sugimoto M, Emmenegger U, Oscroft E, Shaw B, Winter M, Hosius C, Clarke N. Association of baseline characteristics with adverse events (AEs) in the PROpel trial of olaparib (ola) plus abiraterone (abi) as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC). JOURNAL OF CLINICAL ONCOLOGY. 2024.